MIRA INFORM REPORT

 

 

Report No. :

306411

Report Date :

09.02.2015

 

IDENTIFICATION DETAILS

 

Name :

GRUPO GYLSA SA DE CV

 

 

Registered Office :

Av. Rio Lerma 32 Col. Industrial, Laxcolpan, 54030 Tlalnepantla, Edo. De México

 

 

Country :

Mexico

 

 

Date of Incorporation :

06.08.1997

 

 

Legal Form :

Sociedad Anonima De Capital Variable

 

 

Line of Business :

·         engaged in the Import, Export, and Distribution of Raw Materials for the Pharmaceutical Industry.

Subject offer a wide range of Excipients, Active Pharmaceutical Ingredients (including Oncology Biotechnology and Antiretrovirals) and Co-Defendants to provide Productive Solutions to the Pharmaceutical Industry.

Engaged in providing Technical Consultancy Services in the development of Pharmaceutical Formulations and Unitary Operation such as: Particle Size Distribution & X-Ray Crystallography

 

 

No of Employees :

25

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory 

Payment Behaviour :

Slow but Correct

Litigation :

Clear 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – December 31, 2014

 

Country Name

Previous Rating

(30.09.2014)

Current Rating

(31.12.2014)

Mexico

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

Mexico ECONOMIC OVERVIEW

 

Mexico's $1.3 trillion economy has become increasingly oriented toward manufacturing in the 20 years since the North American Free Trade Agreement (NAFTA) entered into force. Per capita income is roughly one-third that of the US; income distribution remains highly unequal. Mexico has become the United States' second-largest export market and third-largest source of imports. In 2013, two-way merchandise trade reached nearly $507 billion. Mexico has free trade agreements with over 50 countries including Guatemala, Honduras, El Salvador, the European Free Trade Area, and Japan - putting more than 90% of trade under free trade agreements. In 2012 Mexico formally joined the Trans-Pacific Partnership negotiations and formed the Pacific Alliance with Peru, Colombia and Chile. Mexico's current government, led by President Enrique PENA NIETO, emphasized economic reforms during its first year in office, passing education, energy, financial, fiscal and telecommunications reform legislation. The three-party "Pact for Mexico" reform agenda aims to improve competitiveness and economic growth across the Mexican economy

 

Source : CIA

 

 

Company summary

 

Legal Name:

GRUPO GYLSA SA DE CV

Trade Name:

GYLSA 

RFC:

GGY970806671

Date Created:

1997

Date Incorporated:

August 6, 1997

Legal Address:

Av. Rio Lerma 32 Col. Industrial, laxcolpan, 54030 Tlalnepantla, Edo. de México

Operative Address:

Av. Rio Lerma 32 Col. Industrial, laxcolpan, 54030 Tlalnepantla, Edo. de México

Telephone:

52 (55) 5611-4565

Fax:

52 (55) 5384-2193

Legal Form:

Sociedad Anonima de Capital Variable

Email:

admon1@gylsa.com.mx

Registered in:

Mexico

Website:

www.gylsa.com.mx

Manager:

Marco Tulio Morales, General manager

Staff:

25

Activity:

Pharmaceutical Products Manufacture Industry

BANKS

Banamex

 

The company does not make its banking details public

HISTORY

 

 

Grupo Gylsa, S.A. de C.V. is a 100% Mexican company established on 1997 and started its activities as an Import Warehouse in 2004 in Mexico City .

PRINCIPAL ACTIVITY

·         engaged in the Import, Export, and Distribution of Raw Materials for the Pharmaceutical Industry.

Subject offer a wide range of Excipients, Active Pharmaceutical Ingredients (including Oncology Biotechnology and Antiretrovirals) and Co-Defendants to provide Productive Solutions to the Pharmaceutical Industry.

Engaged in providing Technical Consultancy Services in the development of Pharmaceutical Formulations and Unitary Operation such as: Particle Size Distribution & X-Ray Crystallography

Products/Services description:

It also has a product line of over 150 products, some of which include: APIs, recipients and other specialty products.

Brands:

GYLSA

Sales are:

Wholesale

Clients:

Pharmaceutical Industry

Suppliers:

METROCHEM API PVT., LTD.
India

Windmoeller & Hoelscher KG
Germany

Operations area:

National

The company imports from

India, Europe

The company exports to

No exports

The subject employs

25 employees

Payments:

Slow but correct

 

 

LOCATION

 

Headquarters :

Av. Rio Lerma 32 Col. Industrial, laxcolpan, 54030 Tlalnepantla, Edo. de México

Branches:

The company does not have any branches.

Industry:

Companies in this industry manufacture and process pharmaceutical products.

Demand for pharmaceuticals is driven by the desire to cure illness and disease. The profitability of individual companies depends on their ability to discover and market new drugs. Large companies benefit from their economies of scale in research, manufacturing, and marketing. Small companies can compete effectively by specializing in drugs that target one or two specific ailments and by partnering with larger drugmakers. 

Drugs are chemicals with beneficial biological activity. Modern drug development is an outgrowth of recent research into the specific causes of illness and disease, coupled with advances in chemistry and industrial technology that allow scientists to manufacture chemicals to improve these conditions.

 

 

GROUP STRUCTURE AND SUBSIDIARY COMPANIES

 

Listed at the stock exchange:

NO

Capital:

NA

Shareholders %:

This is a private company. The major holder is Marco Tulio Morales.

Management:

Marco Tulio Morales, General manager
Gabriela López González, Manager

Related Companies

In order to strengthen globalization of Gylsa as well as to promote searching of new market niches, on March 14th 2013, Marco Tulio Morales MSc founded and incorporated Gylsa International Trading Ltd., located in Vancouver, British Columbia, Canada, with the purpose of reaching USA, Canadian, European and Asian market by establishing a business plan with both pharmaceutical and herbal products since it is easier to reach such markets from Canada than from Mexico itself.

FINANCIAL INFORMATION

 

 

This is a private comapny which does not make its financial figures public.

 

 No financial figures could be confirmed for the subject.

LEGAL FILINGS

 

 

There are no legal connected to the subject

SUMMARY

 

 

The company has more than 15 years of experience in the market, and is well established in business.

It has a small sized strcuture.

It has bank accounts with a well known bank and shows recent import activity.

The company is engaged in the import, export, and distribution of raw materials for the pharmaceutical industry with recognized international quality standards.

 

 

RISK INFORMATION

 

 

 

DEBTS

Controlled

PAYMENTS

Slow but correct

CASH FLOW

Normal

STATUS

Active

 

 

ENTERVIEW

 

NAME

Laura

POSITION

Administrative

COMMENTS

She confirmed address, staff, activity, manager.

 

 

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.61.74

UK Pound

1

Rs.94.65

Euro

1

Rs.70.79

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.